Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009/10

Vaccine

Volumn 28, Issue 33, 2010, Pages 5467-5472

  Kraigher, Alenka ^a   Učakar, Veronika ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

Author keywords

Adverse events following immunization; Pandemic influenza vaccination; Vaccination

Indexed keywords

INFLUENZA VACCINE;

ACUTE APPENDICITIS; ACUTE RESPIRATORY FAILURE; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BRAIN DISEASE; CARDIOTOXICITY; CHILD; CONVULSION; CORONARY ARTERY DISEASE; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SURVEILLANCE PROGRAM; EAR DISEASE; EYE DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEART ARREST; HEART ARRHYTHMIA; HERPES LABIALIS; HERPES ZOSTER; HUMAN; HYPERHIDROSIS; INFANT; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; INSOMNIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MENINGITIS; MENSTRUATION DISORDER; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEURITIS; NEUROLOGIC DISEASE; PAIN; PANDEMIC INFLUENZA; PARESTHESIA; PHYSICIAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SELF EVALUATION; SKIN MANIFESTATION; SLOVENIA; SORE THROAT; STOMACH PAIN; SYNCOPE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TINNITUS; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNIZATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; RISK FACTORS; SLOVENIA;

EID: 77955056838     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.066     Document Type: Article

References (23)

1. Center for Disease Control and Prevention (CDC) Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009, 58(15):400-402.
2. World Health Organization (WHO). Pandemic influenza preparedness and response. WHO guidance document. 2009. Available at [accessed on 27.02.2010]. http://www.who.int/csr/disease/influenza/PIPGuidance09.pdf.
3. World Health Organization (WHO). Characteristics of the emergent influenza A (H1N1) viruses and recommendations for vaccine development. 2009. Available at [accessed on 27.02.2010]. http://www.who.int/csr/resources/publications/swineflu/H1N1Vaccinevirusrecommendation26May2009.pdf.
4. Palache B., Krause R. Progress with human H5N1 vaccines: a perspective from industry. Expert Rev Vaccines 2009, 8(Apr (4)):391-400.
5. Johansen K., Nicoll A., Ciancio B.C., Kramarz P. Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill 2009, 14(41):19361.
6. European Medicines Agency. Pandemic influenza A(H1N1)v vaccines authorised via the core dossier procedure. Explanatory note on scientific considerations regarding the licensing of pandemic A(H1N1)v vaccines. 2009. Available at: [accessed on 27.02.2010]. http://www.emea.europa.eu/pdfs/human/pandemicinfluenza/60825909en.pdf.
7. Carter N.J., Plosker G.L. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 2008, 22(5):279-292.
8. Vellozzi C., Burwen D.R., Dobardzic A., Ball R., Walton K., Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009, 27(15):2114-2120.
9. Chu D.W., Hwang S.J., Lim F.S., Oh H.M., Thongcharoen P., Yang P.C., et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009, 27(52):7428-7435.
10. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009, 9(8):1057-1071.
11. Grgič Vitek M, Učakar V, Metličar T, Sevljak Jurjevec M, Kraigher A. Neželeni učinki pridruženi cepljenju v Sloveniji v letu 2008. Letno poročilo. Inštitut za varovanje zdravja Republike Slovenije, (Immunization-related adverse events in Slovenia in 2008. Annual Report. National Institute of Public Health) 2009. Available at [accessed on 27.02.2010]. http://www.ivz.si/javne_datoteke/datoteke/1210-NezelenicucinkicpridrizeniccepljenjucvcSlovenijicvcletuc2008.pdf.
12. Black S., Eskola J., Siegrist C.A., Halsey N., Macdonald N., Law B., et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009, 19(374(9707)):2115-2122.
13. Eurosurveillance editorial team ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe. Euro Surveill 2009, 14(39).
14. Lakemedelsverket. Medical products agency. Summary of adverse drug reaction reports in Sweden with Pandemrix received through January 8. 2010. Available at [accessed on 28.02.2010]. http://www.lakemedelsverket.se/english/All-news/NYHETER-2010/Summary-of-Adverse-Drug-Reaction-reports-in-Sweden-with-Pandemrix-received-through-January-8/.
15. Medicines and Healthcare products Regulatory Agency (MHRA) UK Suspected Adverse Reaction Analysis. Swine Flu (H1N1) Vaccines - Celvapan and Pandemrix February 2010, Available at http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con071049.pdf [accessed on 28.02.2010].
16. Centers for Disease Control and Prevention (CDC) Safety of influenza A (H1N1) 2009 monovalent vaccines-United States, October 1-November 24, 2009. MMWR Morb Mortal Wkly Rep 2009, 58(48):1351-1356.
17. Iskander J., Broder K. Monitoring the safety of annual and pandemic i vaccines: lessons from the US experience. Expert Rev Vaccines 2008, 7(1):75-82.
18. Griffin M.R., Braun M.M., Bart K.J. What should an ideal vaccine postlicensure safety system be?. Am J Public Health 2009, 99(Suppl. 2):S345-S350.
19. Lantos J.D., Jackson M.A., Opel D.J., Marcuse E.K., Myers A.L., Connelly B.L. Controversies in vaccine mandates. Curr Probl Pediatr Adolesc Health Care 2010, 40(3):38-58.
20. Centers for Disease Control and Prevention.Surveillance Summaries Surveillance for Safety After Immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR 2003, 52(No. SS-1).
21. Lippi G., Targher G., Franchini M. Vaccination, squalene and anti-squalene antibodies: facts or fiction?. Eur J Intern Med 2010, 21(2):70-73.
22. Leroux-Roels I., Roman F., Forgus S., Maes C., De Boever F., Dramé M., et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28(3):849-857.
23. Haber P., Sejvar J., Mikaeloff Y., DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Saf 2009, 32(4):309-323.